Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Taizhou Mabtech Pharmaceuticals
- 23 Apr 2018 Status changed from not yet recruiting to recruiting.
- 10 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 05 Jul 2017 New trial record